Related Experiment Video
Updated: Sep 3, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review
Shista Priyadarshini1, Derek B Allison2,3, Aman Chauhan3,4
1Internal Medicine, Guthrie Robert Packer Hospital, Sayre, PA 18840, USA.
Abstract:
Somatostatin receptors (SSTR) are expressed in various neoplasms and can be targeted for both diagnostics as well as therapeutics. This systematic review aims to compile and discuss the prevalence of somatostatin receptor expression in various neoplasms. We performed a literature search from Google Scholar and PubMed using relevant keywords to look for all publicly available data regarding SSTR expression in various cancers. Both histopathological and radiographical studies were included for SSTR assessment. We found that many cancers express SSTR with varying prevalence. SSTR is now a well-established theranostics biomarker. We now have highly sensitive and specific diagnostic modalities like gallium 68 DOTATATE and copper 64 DOTATATE scans to screen for SSTR-2 and then target it therapeutically with lutetium 177 DOTATATE. A thorough understanding of SSTR expression in other tumors will open the channels for exploring potential SSTR targeting.
Insights
Somatostatin receptors (SSTR) are found in many cancers, making them valuable for diagnosis and treatment. Understanding SSTR expression aids in developing new targeted therapies for various neoplasms.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Somatostatin receptors (SSTR) are present in numerous tumor types.
- SSTRs are increasingly recognized as key targets for cancer diagnostics and therapeutics.
Purpose of the Study:
- To systematically review and discuss the prevalence of somatostatin receptor expression across diverse neoplasms.
- To consolidate current knowledge on SSTR expression for potential theranostic applications.
Main Methods:
- Conducted a systematic literature search using Google Scholar and PubMed.
- Included histopathological and radiographical studies assessing SSTR expression in various cancers.
Main Results:
- Identified varying prevalence of SSTR expression in a wide range of cancers.
- Confirmed SSTR as a well-established theranostic biomarker.
Conclusions:
- Advanced imaging agents like Ga-68 DOTATATE and Cu-64 DOTATATE enable SSTR-2 screening and targeted therapy with Lu-177 DOTATATE.
- Further understanding of SSTR expression in tumors can unlock new therapeutic strategies.
